Press Releases

Notification and public disclosure of transactions by PDMR and persons closely associated with them

By July 18, 2016No Comments

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that on 15 July 2016 it was notified that Amphion Innovations plc (“Amphion”) had pledged an additional 1,400,000 ordinary shares of 1 penny each in the capital of Motif Bio as security to a draw-down of an additional tranche of Amphion’s loan facility (the “Share Pledge”).  In total, Amphion has pledged 16,306,145 ordinary shares in the Company in relation to the Share Pledge.  As a result of the Share Pledge, Amphion will transfer legal title to but will retain the beneficial interest in these pledged ordinary shares. Richard Morgan and Robert Bertoldi, non-executive Chairman and executive director of the Company respectively, are also directors of Amphion (the “Amphion Directors”). Amphion is therefore a “Person Closely Associated” with the Amphion Directors under the Market Abuse Regulation.

The Share Pledge does not change the number of ordinary shares of the Company in issue.

Download the Full Release (PDF)


Motif Bio plc

Graham Lumsden, Chief Executive Officer
[email protected]

Zeus Capital Limited (Nominated Advisor and Broker)

Phil Walker / Giles Balleny
Dominic Wilson
+44 (0) 20 3829 5000

Northland Capital Partners Limited (Broker)

Patrick Claridge / David Hignell
John Howes / Rob Rees (Broking)
+44 (0) 207 382 1100

Walbrook PR Ltd. (Public and Investor Relations)

Paul McManus / Mike Wort
Main: +44 (0)20 7933 8780
Paul: +44 (0)7980 541 893
Mike: +44 (0)7900 608 002
[email protected]

MC Services AG (European IR)

Raimund Gabriel
+49 (0) 89 210 2280

Notes to Editors

Motif Bio is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus).  Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria,